A Research Study Looking at Specific Tissue of the Umbilical Cord
The purpose of this study is to isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
Varices of Umbilical Cord
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Decellularization of Umbilical Cord Wharton's Jelly for Tissue Regenerative Applications Including Avascular Necrosis|
- Isolation and decellularization of umbilical cord Wharton's jelly matrix [ Time Frame: Immediately upon delivery ] [ Designated as safety issue: No ]Use the Wharton's Jelly matrix as a scaffold, we should be able to remove the cellular components of Wharton's Jelly. This decellularization process will help decrease antigenicity and accordingly avoid allosensitization. Additionally, the matrix should be able to provide a 3 dimensional (3D) environment needed for biologic and geometric recellularization.
- Study the ability of the isolated and decellularized matrix to support recellularization with mesenchymal stem cells and to support their growth and differentiation [ Time Frame: Within 24 hours ] [ Designated as safety issue: No ]Use the decellularized matrix for tissue regeneration purposes, it should be able to support recellularization with undifferentiated mesenchymal stem cells and help support their differentiation into different tissues, including bone or cartilage.
Biospecimen Retention: Samples With DNA
umbilical cord tissue
|Study Start Date:||June 2010|
|Estimated Study Completion Date:||June 2016|
|Estimated Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
Our working hypothesis is that umbilical cord blood Wharton's Jelly matrix has all the biochemical and biomechanical characteristics needed in an ideal scaffold for tissue engineering. Accordingly, we expect matrix to support the growth and differentiation of transplanted mesenchymal stem cells. The first step in this effort is to isolate Wharton's Jelly matrix by decellularization. The second step will be to test the ability of this matrix to support the growth and differentiation of transplanted mesenchymal stem cells. The third step will be to pursue preliminary animal testing to study the ability of this matrix to support bone tissue regeneration in vivo.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01166776
|Contact: Omar Aljitawi, MDfirstname.lastname@example.org|
|Contact: Jenny Bunchemail@example.com|
|United States, Kansas|
|University of Kansas Medical Center||Recruiting|
|Kansas City, Kansas, United States, 66160|
|Contact: Omar Aljitawi, MD 913-588-6030 firstname.lastname@example.org|
|Contact: Jenny Bunch, RN 913-945-7713 email@example.com|
|Principal Investigator: Omar Aljitawi, MD|
|Sub-Investigator: Michael Detamore, PhD|
|Sub-Investigator: Rama Garimella, PhD|
|Sub-Investigator: Lisa Stehno-Bittel, PhD|
|United States, Missouri|
|Children's Mercy Hospital||Recruiting|
|Kansas City, Missouri, United States, 64108|
|Sub-Investigator: Richard Hopkins, MD|
|Sub-Investigator: Donna Pacicca, MD|
|St. Louis Cord Blood Bank & Cellular Therapy Laboratory at SSM Cardinal Glennon Children's Medical Center||Recruiting|
|St. Louis, Missouri, United States, 63110|
|Contact: Salem Akel, PhD 314-678-5451 firstname.lastname@example.org|
|Sub-Investigator: Salem Akel, PhD|
|Principal Investigator:||Omar Aljitawi, MD||University of Kansas|